Mayne Pharma Group Ltd
ASX:MYX

Watchlist Manager
Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd
ASX:MYX
Watchlist
Price: 6.48 AUD Market Closed
Market Cap: 526.5m AUD

Wall Street
Price Targets

MYX Price Targets Summary
Mayne Pharma Group Ltd

Wall Street analysts forecast MYX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MYX is 7.55 AUD with a low forecast of 7.47 AUD and a high forecast of 7.77 AUD.

Lowest
Price Target
7.47 AUD
15% Upside
Average
Price Target
7.55 AUD
16% Upside
Highest
Price Target
7.77 AUD
20% Upside
Mayne Pharma Group Ltd Competitors:
Price Targets
002294
Shenzhen Salubris Pharmaceuticals Co Ltd
12% Upside
4578
Otsuka Holdings Co Ltd
38% Upside
RX
Biosyent Inc
2% Upside
GUD
Knight Therapeutics Inc
33% Upside
CRON
Cronos Group Inc
26% Upside
PHO
Photocure ASA
65% Upside
293480
Hana Pharm Co Ltd
62% Upside

Revenue
Forecast

Revenue Estimate
Mayne Pharma Group Ltd

For the last 6 years the compound annual growth rate for Mayne Pharma Group Ltd's revenue is -5%. The projected CAGR for the next 3 years is 10%.

-5%
Past Growth
10%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Mayne Pharma Group Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
19%
Average Beat

Net Income
Forecast

Net Income Estimate
Mayne Pharma Group Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MYX's stock price target?
Price Target
7.55 AUD

According to Wall Street analysts, the average 1-year price target for MYX is 7.55 AUD with a low forecast of 7.47 AUD and a high forecast of 7.77 AUD.

What is Mayne Pharma Group Ltd's Revenue forecast?
Projected CAGR
10%

For the last 6 years the compound annual growth rate for Mayne Pharma Group Ltd's revenue is -5%. The projected CAGR for the next 3 years is 10%.

Back to Top